The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
ScherHIBeerTMHiganoCS. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet.2010;375:1437–1446.
2.
ScherHIFizaziKSaadF. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197.
EghtedarAVertovsekSEstrovZ. Phase 2 study of JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood.2012;119(20):4614–4618.
5.
HarrisonCKiladijanJJKathrinH. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med.2012;36(6):787–798.
6.
ShiJGChenXEmmT. The effect of CYP3A4 inhibition or induction on the pharmacokinetic and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol.2012;52:809–818.
7.
ShiJGChenXMcGeeRF. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol.2011;51:1644–1654.
8.
ShillingADNedzaFMEmmT. Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos.2010;38:2023–2031.
9.
VertovsekSKantarjianHRubenMA. Safety and efficacy of INCB018424, as JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med.2010;363:1117–1127.
10.
VertovsekSMesaRAGotlibJ. A double-blind placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med.2012;36(6):799–807.
